Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Exemestane|DRUG: Anastrozole
Sponsor: Spanish Breast Cancer Research Group
Collaborators: Pfizer